PROCESS FOR PRODUCING A MONOPHASIC PHARMACEUTICAL PRODUCT FOR LIMITING/REDUCING THE RISK OF DEEP VEIN THROMBOSIS UNITED WITH ORAL CONTRACEPTION

摘要

Monophasic oral contraceptives comprising a combination of 2.0 mg of dienogest and 0.030 mg of ethinylestradiol or 2.0 mg of dienogest and 0.020 mg of ethinylestradiol for nx21 daily dose units with subsequent, after nx21, use of a maximum of 7 daily intake-free or placebo-containing dose units, where n is equal to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and 17, achieve a limitation/reduction of the risk of deep vein thrombosis united with oral contraception. A suitable contraceptive composition with prolonged intake time of the hormone-containing daily dose units is provided and, despite the prolonged intake time, keeps the risk of deep vein thrombosis at the same level as with corresponding conventional oral contraceptives and thus within acceptable limits.